Sulfadoxine-pyrimethamine efficacy and selection of Plasmodium falciparum DHFR mutations in Burkina Faso before its introduction as intermittent preventive treatment for pregnant women. by Tinto, Halidou et al.
Tinto, H; Oudraogo, JB; Zongo, I; van Overmeir, C; van Marck, E;
Guiguemd, TR; D’Alessandro, U (2007) Sulfadoxine-pyrimethamine
efficacy and selection of Plasmodium falciparum DHFR mutations in
Burkina Faso before its introduction as intermittent preventive treat-
ment for pregnant women. The American journal of tropical medicine
and hygiene, 76 (4). pp. 608-13. ISSN 0002-9637
Downloaded from: http://researchonline.lshtm.ac.uk/4175/
DOI:
Usage Guidelines
Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alterna-
tively contact researchonline@lshtm.ac.uk.
Available under license: Copyright the publishers
SULFADOXINE–PYRIMETHAMINE EFFICACY AND SELECTION OF PLASMODIUM
FALCIPARUM DHFR MUTATIONS IN BURKINA FASO BEFORE ITS
INTRODUCTION AS INTERMITTENT PREVENTIVE TREATMENT FOR
PREGNANT WOMEN
HALIDOU TINTO, JEAN BOSCO OUÉDRAOGO, ISSAKA ZONGO, CHANTAL VAN OVERMEIR, ERIC VAN MARCK,
TINGA ROBERT GUIGUEMDÉ, AND UMBERTO D’ALESSANDRO*
Centre Muraz, Bobo Dioulasso, Burkina Faso; Institut de Recherche en Sciences de la Santé, Bobo Dioulasso, Burkina Faso;
University of Antwerp, Antwerp, Belgium; Prince Leopold Institute of Tropical Medicine, Antwerp, Belgium
Abstract. Sulfadoxine-pyrimethamine efficacy was determined with a 28-day follow-up in 97 children between 6
months and 15 years of age. The polymerase chain reaction (PCR)-corrected treatment failure was 8.2% and the
uncorrected was 21.6%. The presence of the dihydrofolate reductase (DHFR) and dihydropteroate synthetase (DHPS)
mutations linked to sulfadoxine-pyrimethamine resistance before and after treatment was determined by PCR-
restriction fragment length polymorphism (RFLP) and by a fluorogenic PCR assay. Before treatment, the prevalence of
the triple DHFR mutations was higher among the patients having had a recurrent parasitemia (either recrudescence or
new infection; 28.6% versus 9.3%), although the difference was not significant (P  0.1). The double mutation Ala-
436/Gly-437 was observed in 67% of samples, whereas no Glu-540 mutation was found. After treatment, the triple
DHFR mutation was found in 76.2% of patients with recurrent parasitemia, recrudescence, and new infection alike. Such
high prevalence of mutant parasites indicates that sulfadoxine-pyrimethamine should not be used as monotherapy.
INTRODUCTION
In Africa, sulfadoxine-pyrimethamine (SP) has been used
as a second-line drug for the treatment of chloroquine-
resistant (CQ-R) malaria.1 However, CQ-R is now so wide-
spread that several countries such as Burundi (from CQ to
amodiaquine-artesunate), Rwanda (from CQ to amodi-
aquine-SP), Uganda (from CQ-SP to artemether-
lumefantrine), and Zambia (from SP to artemether-
lumefantrine) have changed or are about to change their drug
policy.2
Pyrimethamine inhibits dihydrofolate reductase (DHFR),
whereas sulfadoxine inhibits dihydropteroate synthetase
(DHPS).3–5 The understanding of the molecular mechanisms
of parasite resistance to anti-folates has led to a proliferation
of laboratory and field studies investigating the role of mo-
lecular markers in detecting drug resistance. DHFR muta-
tions at Asn-51 to Ile-51 and Cys-59 to Arg-59 in association
with Asn-108 were found to be associated with greater resis-
tance to pyrimethamine,4 whereas P. falciparum strains with
variable levels of sensitivity to sulfadoxine had sequence
variation in the DHPS gene.5,6
In Burkina Faso, until recently, CQ and SP have been used
as first- and second-line drugs, respectively, for the treatment
of uncomplicated malaria. However, in vivo tests carried out
in 2002 in Nanoro (center of the country) showed clinical
failure (early and late) to CQ of > 50% (J. B. Ouédraogo,
personal communication). The first SP treatment failure was
observed in 19991 and a study conducted in 2001, a time when
SP was still used as second-line treatment, reported about 4%
resistance (J. B. Ouédraogo, personal communication). Such
data have prompted the change of the anti-malarial drug
policy, more specifically to the adoption of artemether-
lumefantrine as first-line treatment of uncomplicated malaria
and to the use of SP intermittent preventive treatment (IPT)
during pregnancy instead of CQ weekly.7 Indeed, in Mali, a
neighboring country, SP IPT during the second and third tri-
mester was shown to be more efficacious than weekly CQ in
preventing malaria infection and its consequences on the
mother’s and newborn’s health.8 In Burkina Faso, all studies
on SP efficacy conducted thus far used a 14-day follow-up9
that under-estimates failure rate.10 Considering the high
CQ-R in Nanoro and the low SP efficacy in some neighboring
countries such as Côte d’Ivoire and Ghana,11,12 the relation-
ship between SP treatment failures (28-day follow-up) and
the selection of the DHFR and DHPS mutations in children
living in Nanoro was studied before the introduction of SP
IPT. Such data might help in estimating the probable impact
of SP IPT during pregnancy.
MATERIALS AND METHODS
Study sites. The study was carried out in 2003 in Nanoro,
situated in the center of Burkina Faso at 85 km from Ouaga-
dougou, the capital city. The rainy season occurs from June to
October (average rainfall: 700 mm/yr; mean temperature >
30°C), and it is followed by a cold dry season from November
to February (minimum temperature, 15°C) and a hot dry sea-
son from March to May. The population was estimated at
136,209 inhabitants in 2001; 19% of them are children < 5
years of age. Malaria is hyperendemic with seasonal transmis-
sion. The entomological inoculation rate (EIR) is estimated
at 50–60 infective bites/man/yr (A. Diabate, personal commu-
nication). The most common vectors are Anopheles gambiae,
A. funestus, and A. arabiensis. Plasmodium falciparum is the
predominant malaria parasite. Malaria is the main reason for
consultations at health facilities all year round, with a peak
between September and December. In 2000, malaria repre-
sented 34% (21,039/62,400) of the total consultations in the
district (District’s health statistics).
Study population. This is part of a larger study that inves-
tigated CQ and SP efficacy in children between 6 months and
15 years of age in Burkina Faso. In the following analysis,
only SP efficacy in Nanoro, the only site where we conducted
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a 28-day follow-up, has been considered. Details of the study
methodology have been described in detail elsewhere.1
Briefly, children with fever (axillary temperature  37.5°C)
and a P. falciparum infection with a parasite density between
2,000 and 100,000/L were recruited if the parent or guardian
gave informed consent. This study was reviewed and ap-
proved by the Center Muraz Ethical Committee.
Treatment and follow-up. The World Health Organization
(WHO) 28-day in vivo test was carried out.13 SP was admin-
istered orally and according to body weight (25 mg/kg of sul-
fadoxine stat). All doses were given under direct supervision.
Children were observed for at least 30 minutes, and a replace-
ment dose was given when vomiting occurred. When vomiting
persisted, children were withdrawn from the study. Axillary
temperature and clinical information were collected at days 0,
1, 2, 3, 7, 14, 21, and 28 after treatment. Thick and thin blood
films were collected at days 0, 3, 7, 14, 21, and 28.
Definitions of outcomes. Outcomes were defined according
to the WHO-modified classification for monitoring anti-
malarial drug resistance: early treatment failure (ETF), late
clinical failure (LCF), late parasitological failure (LPF), and
adequate clinical and parasitological response (ACPR).13
Late treatment failure (LTF) is defined as the sum of LCF
and LPF, whereas total treatment failure (TTF) is defined as
the sum of ETF, LCF, and LPF.
Molecular analysis. All samples from patients with recur-
rent parasitemia during follow-up were systematically geno-
typed in addition to about one half of randomly selected
ACPRs. Blood samples for the molecular analysis were col-
lected on filter paper (Whatman 3, Whatman International,
Ltd., Maidstone, UK) at day 0 before treatment and at the
time of parasitemia reappearance. DNA was extracted using
the Chelex-100 method.14
Detection of the DHFR and DHPS mutations. We analyzed
three point mutations both in the DHFR gene (108, 51, and
59) and the DHPS gene (436, 437, and 540). Details of poly-
merase chain reaction (PCR) conditions are summarized in
Table 1. The detection of mutations in DHPS and Asn/Thr-
108 in DHFR was done using PCR followed by restriction
fragment length polymorphism (RFLP).15,16 The first-round
PCR amplification was performed in a 25-L mixture con-
taining 1× PCR buffer (Promega, Madison, WI), 2.5 mmol/L
MgCl2 (Promega), 0.2 mmol/L of dNTPs, 0.5 pmol of each
primer, 1 U of Taq polymerase (Promega), and 1 L of ex-
tracted parasite DNA. Nested PCR was performed in a 50-L
mixture containing 1 L of primary PCR product. The am-
plified DNA fragments were separated by electrophoresis in
a 2% agarose gel. The nested PCR product was subjected to
enzyme (New England Biolabs) digestion. For the DHFR 108
mutations, AluI cuts only the wild-type gene (Ser-108) into
323 and 372 bp, BsrI cuts only the mutant gene (Asn-108) into
328 and 372 bp, and ScrfI cuts only the mutant gene (Thr-108)
into 324 and 376 bp. For the DHPS mutations, MspAI cuts
only the mutant gene (Ala-436) into 300 and 851 bp, AvaII
cuts only the mutant gene (Gly-437) into 303 and 848 bp, and
FokI cuts only the mutant gene (Glu-540) into 538 and 326 bp.
For each series of samples, water was used as a negative
control. For the detection of Asn-108, 3D7-clone DNA was
used as the wild-type control and Dd2-DNA was used as the
mutant control. For the detection of DHPS mutations, PS-
Mali-clone DNA was used as wild-type control for positions
437 and 540 and mutant control for the position 436, whereas
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PS-Peru-clone DNA was used as wild-type control for the
position 436 and mutant control for positions 437 and 540.
The detection of DHFR Ile-51 and Arg-59 mutations was
done by using a fluorogenic PCR assay that combines fluo-
rescence–resonance energy transfer between fluorophores
present on a probe and a PCR primer and a melt-curve analy-
sis.17 The basis of this assay is fluorescence resonance energy
transfer (FRET), which requires two fluorophores referred to
as donor and acceptor. On hybridization of the fluorogenic
probes on the amplicon, these fluorophores are brought into
close proximity. The fluorescence emitted from the donor is
then absorbed by the acceptor resulting in fluorescence emis-
sion by the acceptor, which can be detected. Progressive in-
crease of the temperature during melt curve analysis leads to
the dissociation of the fluorogenic probes from the target at
specific temperatures, resulting in the loss of fluorescent sig-
nal visualized on a melt curve. The specific temperature of
probe melting depends on the thermodynamic stability and
allows discrimination of perfectly complementary and mis-
matched probe-target duplexes. The assay allows 1) the iden-
tification of the genotype at multiple codons simultaneously
in a mutation hot spot region (codons 50-60) of the P. falci-
parum DHFR gene and 2) the quantification of different
genotypes present in a polyclonal malaria infection. For the
detection of DHFR Ile-51 and Arg-59 mutations, it allows the
identification of the genotype at double codons Ile-51/Arg-59
simultaneously (when existing) or one of the two single mu-
tations alone.
The second-round PCR amplification was performed in a
50-L mixture containing 1 L of primary PCR product re-
sulting from amplification with AMP1 and AMP2, 1× PCR
buffer iQ Supermix (Bio-Rad), 500 nmol/L of primer FRET3
(Rox), and 100 nmol/L of primer FRET2. The probe DHFR
(FAM): 5-CACAAAAATATTTCATATCTAGGGAAT-
TACAT-3 was then added immediately after amplification,
in a final concentration of 160 nmol/L. The iCycler (Bio-Rad,
Hercules, CA), a standard PCR cycler equipped with an op-
tical module, was used to perform the melt-curve analysis
(MCA) as described by Decuypere and others.17 The MCA
protocol consisted of two steps: 1) 1 minute at 94°C and 2) 110
repeated heatings (each for 30 seconds), starting at 48°C and
with increments of 0.3°C. Change in fluorescence appears as
a positive peak on a plot of the first negative derivative of the
fluorescence/temperature function. All experiments using
FRET/MCA were performed in triplicate to ensure reproduc-
ibility. Plasmids containing a DHFR insert with a known ge-
notype were obtained from MR4/American Type Culture
Collection. FR-3D7, with the genotype 50 Cys (TGT)-51 Asn
(AAT)-59 Cys (TGT) (Tm: 62.4°C) was used as the wild-type
control, and FR-V1S, with the genotype 50 Cys (TGT)-51 Ile
(ATT)-59 Arg (CGT) (Tm: 52.8°C) was used as the mutant
control. Four other controls (N2, N5, N7, and N15) defined on
the basis of significant and reproducible (inter-experiment SD
< 0.4°C) differences in Tm were also used.17
Genotyping to distinguish between recrudescence and new
infection. If a patient had recurrent parasitemia, blood
samples from day 0 and from that the day of parasitemia
reappearance were used to genotype parasite strains. Nested
PCR18 was adopted for the analysis of two polymorphic ge-
netic markers from P. falciparum: merozoïte surface proteins
1 and 2 (MSP1 and MSP2; Table 1). A recrudescent infection
was defined as one that showed match in size of at least one
allele for both the MSP1 and MSP2 genes between day 0 and
the day of recurrent parasitemia.
Statistical methods. Data were entered in Excel version 97
and analyzed using STATA 8 (Stata Corp. 2003). Children
were considered not to be clinical failures if their parasitemia
between day 14 and day 28 was classified as a new rather than
recrudescent infection. Frequencies of DHFR point muta-
tions Asn-108, Ile-51, and Arg-59 were determined before
and after treatment (the latter for recrudescent and new in-
fections), whereas those of the DHPS point mutations Ala-
436, Gly-437, and Glu-540 were determined only before treat-
ment. 2 test was used to test for significant differences be-
tween categorical variables. A value of P < 0.05 was
considered statistically significant.
RESULTS
Of 673 children screened, 63% (424) had a microscopically
confirmed malaria infection, and of these, 110 were enrolled
in the SP treatment group. The mean age of the children was
51.5 months (95% CI, 45.3–57.7), 60% (66/110) of them being
< 5 years of age. Outcome at day 28 is known for 97 (88.2%)
patients who completed the follow-up (8 were lost to follow-
up, 1 developed another illness, 1 had severe malaria, and 3
withdrew the informed consent). There was no ETF. Up to
day 14, only two (2%) patients had recurrent parasitemia; 19
(19.6%) additional recurrent parasitemias were observed be-
tween day 15 and 28. All these infections were successfully
genotyped, and eight (42.1%) of them were classified as re-
crudescence so that PCR-corrected TTF was 8.2% (8/97) and
the ACPR was 91.8% (Table 2).
The DHFR gene was successfully genotyped for the detec-
tion of the Asn-108 mutation in 53 samples: the 21 recurrent
parasitemias and 32 randomly selected ACPRs. Twenty-two
(41.5%) samples did not carry any DHFR mutation (14
ACPR, 7 new infections, and 1 TTF; Table 2). Before treat-
ment, the prevalence of the triple DHFR mutations was
TABLE 2
Treatment outcome and DHFR–DHPS mutations before treatment % (n/N)
DHFR (n  53)
DHPS (n  51)
Wild-type S108N
Double mutation
(108-51)
Triple mutation
(108-051-59) A437G S436A-A437G A437G-K540E
TTF 12.5 (1/8) 25.0 (2/8) 25.0 (2/8) 37.5 (3/8) 25.0 (2/8) 75.0 (6/8) 0.0 (0/8)
New infection 53.8 (7/13) 23.0 (3/13) 0.0 (0/13) 23.0 (3/13) 7.7 (1/13) 84.6 (11/13) 0.0 (0/13)
ACPR 43.7 (14/32) 56.2 (18/32) 15.6 (5/32) 9.3 (3/32) 70.9 (22/31) 54.8 (17/31) 0.0 (0/31)
Values are percentasge (n/N).
TTF, total treatment failures; ACPR, adequate clinical and parasitological response.
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higher among the patients having had a recurrent parasitemia
(either recrudescence or new infection; 28.6% versus 9.3%),
but the difference was not significant (P  0.1; Table 2).
The DHPS mutation Gly-437 was observed in 78.4% (40/
51) of samples analyzed, most of them (77.5%) being mixed
infections with both the mutant and wild alleles (Ala-437).
The double mutation Ala-436/Gly-437 was observed in 67%
(34/51) of samples, and its prevalence was significantly higher
among patients having had recurrent parasitemia than in
those classified as ACPR (P  0.005). No Glu-540 mutation
was observed.
After treatment, 76.2% (16/21) recurrent parasitemias car-
ried the pure triple DHFR mutation, recrudescence, and new
infection alike (Table 3).
DISCUSSION
The first two cases of in vivo resistance to SP in Burkina
Faso were reported in 1990 and 1991 from Bobo Dioulasso.19
Despite its long use as a second-line drug, SP resistance in
Burkina Faso was low, often < 1%.1 However, patients had
always been followed only up to day 14 after treatment, un-
der-estimating the level of treatment failures.10 Indeed, in this
study, the PCR-corrected failure rate at day 28 was much
higher than that observed at day 14, confirming that SP re-
sistance in Burkina Faso is probably higher than that reported
from previous studies.1 Nevertheless, SP is still relatively ef-
ficacious in Burkina Faso20–22 and in several other West Af-
rican countries (treatment failure < 4%),23,24 although a few
areas of high resistance, particularly in forest areas, exist
(parasitological resistance > 20%).11,12 Such patchy distribu-
tion and the relative low SP resistance could be explained by
several factors, more specifically by the limited drug pressure.
This situation might rapidly change as the result of increased
SP use, a consequence of high CQ resistance. A new drug
policy adopted in February 200525 recommends the use of the
combination artemether-lumefantrine as first-line treatment.
In this context, SP, one of the few anti-malarials that can be
safely used during pregnancy, could be deployed exclusively
as IPT, minimizing the drug pressure and the selection of
resistant parasites.
Although the molecular basis of P. falciparum in vitro re-
sistance to the anti-folate drugs is well established,26–28 the
relationship between the identified molecular markers and
therapeutic failure is not a linear one. Indeed, it can vary
according to the geographical situation and/or level of resis-
tance.22,29 High prevalence of the DHFR Asn-108 point mu-
tation was strongly associated with high SP use. In our study,
despite low SP resistance, more than one half of the pre-
treatment samples carried the Asn-108 mutation, a frequency
similar to that observed in some high SP resistance areas.30
Considering the importance of this mutation for the develop-
ment of pyrimethamine resistance,20,31,32 such high preva-
lence might indicate a rapid development of anti-folate resis-
tance in Burkina Faso. We did not find any Thr-108 mutation,
a result consistent with earlier studies,30,33 confirming the rar-
ity of this mutation in Africa.
The use of the fluorogenic PCR assay, allowing the identi-
fication of the double mutation Ile-51/Arg-59, showed that
the Arg-59 mutation was always associated with Ile-51 muta-
tion, confirming the stepwise accumulation of DHFR muta-
tions in the following order: Asn-108→ Ile-51→ Arg-59.22,34
The prevalence of these two mutations was relatively low,
about twice than that of SP resistance, indicating its possible
link with SP resistance, at least in places where this is low.
The DHFR triple mutation, with or without mutant DHPS
alleles, has been associated with SP resistance.35–38 Although
the triple mutation was observed only in a minority of treat-
ment failures, this was observed in almost all samples col-
TABLE 3
DHFR pre-treatment/post-treatment and DHPS pre-treatment genotypes of P. falciparum isolates in treatment failures
Pre-treatment Post-treatment
Samples
DHFR DHPS DHFR
108 51 51/59 436 437 108 51 51/59 MSP1/2 profile
N55 Asn Ile Ile/Arg Ser/Ala Ala/Gly Asn Ile Ile/Arg R
N62 Ser/Asn Asn Asn/Cys Ser/Ala Ala Asn Ile — R
N203 Ser/Asn Asn Asn/Cys Ser/Ala Ala/Gly Asn Ile — R
N434 Ser Asn Asn/Cys Ser/Ala Ala/Gly Asn — Ile/Arg R
N510 Ser/Asn Ile Asn/Cys Ser/Ala Gly Asn Ile Ile/Arg R
N551 Asn — Ile/Arg Ser/Ala Ala Asn — Ile/Arg R
N605 Ser/Asn Ile Asn/Cys Ser/Ala Ala/Gly Asn Ile Ile/Arg R
N638 Asn — Ile/Arg Ser/Ala Ala/Gly Asn — Ile/Arg R
N100 Ser Asn Asn/Cys Ser/Ala Ala/Gly Asn — Ile/Arg NI
N246 Ser Asn Asn/Cys Ser/Ala Ala/Gly Asn Ile — NI
N283 Ser Asn Asn/Cys Ser/Ala Ala/Gly Asn — Ile/Arg NI
N318 Ser/Asn Asn Asn/Cys Ser/Ala Ala/Gly Asn Ile Ile/Arg NI
N351 Ser/Asn Asn Asn/Cys Ser/Ala Gly Asn Ile Ile/Arg NI
N362 Ser Asn Asn/Cys Ser/Ala Gly Asn — Ile/Arg NI
N386 Ser Asn Asn/Cys Ser/Ala Ala/Gly Asn Ile Ile/Arg NI
N441 Ser/Asn Asn Ile/Arg Ser/Ala Ala/Gly Asn Ile Ile/Arg NI
N505 Ser Asn Asn/Cys Ala Ala/Gly Asn — Ile/Arg NI
N515 Ser/Asn Asn Asn/Cys Ala Ala/Gly Asn — Ile/Arg NI
N567 Asn — Ile/Arg Ser Ala Asn Ile — NI
N573 Ser Asn Asn/Cys Ser/Ala Ala/Gly Asn Ile Ile/Arg NI
N598 Ser/Asn Asn Ile/Arg Ser Gly Asn Ile — NI
Mutant genotypes are indicated in bold italics.
R, recrudescence; NI, new infection.
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lected after treatment, confirming that SP treatment selects
these specific mutations, regardless of the outcome. It also
confirms that the DHFR triple mutation is necessary but not
sufficient for SP treatment failure.22–24,26–39 It is interesting to
note that DHFR mutants were also selected in treatment fail-
ures classified later as new infections. Despite the limitation
of the PCR technique used16 and the possibility of misclassi-
fication, this indicates that resistant parasites can be selected
in newly established infections if these occur during the time
SP plasma levels are at sub-therapeutic concentrations.
Therefore, DHFR mutations can rapidly arise and spread as
soon as SP use becomes common.40
Resistance to sulfadoxine has been associated to several
mutations in the DHPS gene.5,6 In our study, no Glu-540
mutation was found, and only Ala-436 and the Gly-437 mu-
tations were found, confirming earlier findings that Ala-436 is
most common where SP use and resistance is lower22,30 and
that it occurs without the Glu-540 mutation.22 Nevertheless,
unlike previous observations,22 in our study, the Ala-436 mu-
tation was found in most isolates with the Gly-437 mutation.
It has been suggested that the Gly-437 mutation is the first
of the DHPS mutations, a situation comparable with the Asn-
108 mutation in the DHFR gene.36 However, our results show
that the frequency of the Gly-437 mutation was similar to that
of the Ala-436 mutation, not supporting this hypothesis. It has
also been suggested that the DHFR Arg-59 and the DHPS
Glu-540 mutations can predict SP treatment failure.34,39 We
were unable to observe this; no sample carried the DHPS
Glu-540 mutation,29 possibly because of the low SP resis-
tance. This might indicate that the DHPS mutations play a
secondary role in determining treatment failure,37 although
the DHFR triple mutations are necessary but not sufficient
for SP resistance.
In conclusion, our results show that SP is still highly effi-
cacious in Burkina Faso. However, considering the relatively
high prevalence of the DHFR and DHPS mutations and,
more importantly, their selection after treatment, SP should
not be used as monotherapy for uncomplicated malaria but
should be specifically targeted to pregnant women as IPT.
The choice of SP as IPT in pregnancy is unavoidable because
alternatives are not available yet. It still needs to be seen what
will be the influence of this policy on the selection of mutant
parasites and eventually on the SP efficacy in preventing ma-
laria during pregnancy.
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